

# **Disclosure Statement Pursuant to the Pink Basic Disclosure Guidelines**

## **AVVAA World Health Care Products, Inc.**

1001 West Loop South, Suite 803  
Houston, TX 77027

---

713-621-6466  
<https://avvaaworldhealth.com/>  
SIC Code: 6162

## **Annual Report**

**For the period ending 05/31/2023 (the “Reporting Period”)**

### **Outstanding Shares**

The number of shares outstanding of our Common Stock was:

966,442,572 as of 05/31/2023

966,442,572 as of 05/31/2022

### **Shell Status**

Indicate by check mark whether the company is a shell company (as defined in Rule 405 of the Securities Act of 1933, Rule 12b-2 of the Exchange Act of 1934 and Rule 15c2-11 of the Exchange Act of 1934):

Yes: ☐ No: ☒

Indicate by check mark whether the company's shell status has changed since the previous reporting period:

Yes: ☐ No: ☒

### **Change in Control**

Indicate by check mark whether a Change in Control<sup>1</sup> of the company has occurred over this reporting period:

Yes ☐: No: ☒

---

<sup>1</sup> “Change in Control” shall mean any events resulting in:

- (i) Any “person” (as such term is used in Sections 13(d) and 14(d) of the Exchange Act) becoming the “beneficial owner” (as defined in Rule 13d-3 of the Exchange Act), directly or indirectly, of securities of the Company representing fifty percent (50%) or more of the total voting power represented by the Company's then outstanding voting securities;
- (ii) The consummation of the sale or disposition by the Company of all or substantially all of the Company's assets;
- (iii) A change in the composition of the Board occurring within a two (2)-year period, as a result of which fewer than a majority of the directors are directors immediately prior to such change; or
- (iv) The consummation of a merger or consolidation of the Company with any other corporation, other than a merger or consolidation which would result in the voting securities of the Company outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into voting securities of the surviving entity or its parent) at least fifty percent (50%) of the total voting power represented by the voting securities of the Company or such surviving entity or its parent outstanding immediately after such merger or consolidation.

**1) Name and address(es) of the issuer and its predecessors (if any)**

In answering this item, provide the current name of the issuer any names used by predecessor entities, along with the dates of the name changes.

The name of the issuer is AVVAA World Health Care Products, Inc.

The previous name of the issuer was Sierra Gigante Resources until July 2002.

The state of incorporation or registration of the issuer and of each of its predecessors (if any) during the past five years; Please also include the issuer's current standing in its state of incorporation (e.g. active, default, inactive):

The issuer was incorporated in the State of Nevada in June 1998 as Sierra Gigante Resources, Inc. The issuer filed an Amendment to the Articles of Incorporation in July 2002 to change the name of the Company to AVVAA World Health Care Products, Inc.

The issuer is incorporated in the State of Nevada in good standing and "Active".

Describe any trading suspension orders issued by the SEC concerning the issuer or its predecessors since inception:

N/A

List any stock split, stock dividend, recapitalization, merger, acquisition, spin-off, or reorganization either currently anticipated or that occurred within the past 12 months:

None.

The address(es) of the issuer's principal executive office:

AVVAA World Health Care Products, Inc.  
c/o Omnis Public Capital Management LLC  
1001 West Loop South, Suite 803  
Houston, TX 77027

The address(es) of the issuer's principal place of business:

☒ *Check if principal executive office and principal place of business are the same address:*

AVVAA World Health Care Products, Inc.  
c/o Omnis Public Capital Management LLC  
1001 West Loop South, Suite 803  
Houston, TX 77027

Has the issuer or any of its predecessors been in bankruptcy, receivership, or any similar proceeding in the past five years?

No: ☐ Yes: ☒ If Yes, provide additional details below:

On January 25, 2021, the District Court of Clark County, Nevada, case number A20-825998-C, entered an Order Granting Application for Appointment (the "Order") of SSM Monopoly Corporation as Custodian of the Company. Pursuant to the Order, SSM Monopoly Corporation (the "Custodian") has the authority to take any actions on behalf of the Company, that are reasonable, prudent or for the benefit of the Company, including, but not limited to, issuing shares of stock and issuing new classes of stock, as well as entering into contracts on behalf of the Company. In addition, the Custodian, pursuant to the Order, is required to meet the requirements under the Nevada charter.

On July 15, 2021, the District Court of Clark County, Nevada entered a Final Order Granting the Motion to Discharge Custodianship to dismiss the Custodian's authority and control over the Company under the Custodianship. On the same

day, Omnis Public Capital Management LLC gained authority and control of the Company through voting rights and the court order.

## 2) Security Information

### **Transfer Agent**

Name: Signature Stock Transfer  
Phone: 972-612-4120  
Email: jason@signaturestocktransfer.com  
Address: 14673 Midway Road - Suite 220, Addison, TX 75001

### **Publicly Quoted or Traded Securities:**

*The goal of this section is to provide a clear understanding of the share information for its publicly quoted or traded equity securities. Use the fields below to provide the information, as applicable, for all outstanding classes of securities that are publicly traded/quoted.*

Trading symbol:	AVVH	
Exact title and class of securities outstanding:	Common Stock	
CUSIP:	002432201	
Par or stated value:	0.001	
Total shares authorized:	4,000,000,000	as of date: 05/31/2023
Total shares outstanding:	966,442,572	as of date: 05/31/2023
Total number of shareholders of record:	100	as of date: 05/31/2023

*All additional class(es) of publicly quoted or traded securities (if any):*

Trading symbol:	_____	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	as of date: _____
Total shares outstanding:	_____	as of date: _____
Total number of shareholders of record:	_____	as of date: _____

Trading symbol:	_____	
Exact title and class of securities outstanding:	_____	
CUSIP:	_____	
Par or stated value:	_____	
Total shares authorized:	_____	as of date: _____
Total shares outstanding:	_____	as of date: _____
Total number of shareholders of record:	_____	as of date: _____

### **Other classes of authorized or outstanding equity securities:**

*The goal of this section is to provide a clear understanding of the share information for its other classes of authorized or outstanding equity securities (e.g. preferred shares). Use the fields below to provide the information, as applicable, for all other authorized or outstanding equity securities.*

Exact title and class of the security:	Special 2021 Series A Preferred Stock	
CUSIP (if applicable):	N/A	
Par or stated value:	0.001	
Total shares authorized:	1	as of date: 05/31/2023
Total shares outstanding (if applicable):	1	as of date: 05/31/2023
Total number of shareholders of record (if applicable)	1	as of date: 05/31/2023

Exact title and class of the security:	Class A Convertible Super Preferred Stock	
CUSIP (if applicable):	N/A	
Par or stated value:	0.001	
Total shares authorized:	400,000,000	as of date: 05/31/2023
Total shares outstanding (if applicable):	1,250,000	as of date: 05/31/2023
Total number of shareholders of record (if applicable)	1	as of date: 05/31/2023

Exact title and class of the security:	Series B Preferred Stock	
CUSIP (if applicable):	N/A	
Par or stated value:	0.001	
Total shares authorized:	20,000,000	as of date: 05/31/2023
Total shares outstanding (if applicable):	15,362,500	as of date: 05/31/2023
Total number of shareholders of record (if applicable)	31	as of date: 05/31/2023

### **Security Description:**

*The goal of this section is to provide a clear understanding of the material rights and privileges of the securities issued by the company. Please provide the below information for each class of the company's equity securities, as applicable:*

#### **1. For common equity, describe any dividend, voting and preemption rights.**

One for one voting rights on all common stock, entitled to dividends as determined by the Board of Directors, no Pre-emptive rights.

#### **2. For preferred stock, describe the dividend, voting, conversion, and liquidation rights as well as redemption or sinking fund provisions.**

**Special 2021 Series A preferred share** - Each 2021 Series A Preferred stockholder is entitled to 60% of all votes entitled to vote. The share of 2021 Series A Preferred Stock shall convert into common shares at a conversion rate of 1 preferred to 2,000,000,000 common shares. The share of 2021 Series A Preferred Stock shall not be entitled to any dividends and shall not participate in any proceeds available to the corporation's shareholders upon the liquidation, dissolution or winding up of the Corporation.

**Class A Convertible Super Preferred** shall have super voting power (5:1 compared to the company's common stock). Each share is convertible into 2 shares of the company's common stock at the option of the holder after one year. A liquidation preference of 8:1 compared to the company's common stock.

**Series B Preferred** shares are convertible into 100 shares of common stock and do not have any voting rights.

*Stock Dividends and Stock Splits.* If the Corporation, at any time while the Series B Preferred Stock is outstanding: (A) shall pay a stock dividend or otherwise make a distribution or distributions on shares of its Common Stock or any other equity or equity equivalent securities payable in shares of Common Stock (which, for avoidance of doubt, shall not include any shares of Common Stock issued by the Corporation pursuant to this Series B Preferred Stock), (B) subdivide outstanding shares of Common Stock into a larger number of shares, (C) combine (including by way of reverse stock split) outstanding shares of Common Stock into a

**Liquidation.** Upon any liquidation, dissolution or winding-up of the Corporation, whether voluntary or involuntary (a "Liquidation"), the Holders shall be entitled to receive out of the assets of the Corporation, whether such assets are capital or surplus, for each share of Series B Preferred Stock an amount equal to the greater of (i) the average price of the Corporation's Common Stock over a period of ten (10) trading days, if the Corporation's Common Stock is listed on a "National Securities Exchange" registered with the SEC under Section 6 of the Securities Exchange Act of 1934 or Over-the-Counter (OTC) securities exchange, or (ii) Two Dollars (\$2.00) per share.

None.

None.

The goal of this section is to provide disclosure with respect to each event that resulted in any changes to the total shares outstanding of any class of the issuer's securities **in the past two completed fiscal years and any subsequent interim period.**

#### A. Changes to the Number of Outstanding Shares

No: ☐ Yes: ☒ (If yes, you must complete the table below)

OTC Markets Group Inc.  
OTC Pink Basic Disclosure Guidelines (v4.0 January 1, 2023)

<u>07/28/2021</u>	<u>Cancellation</u> <u>See (1)</u> <u>Below.</u>	<u>395,000.00</u> <u>See (1)</u> <u>Below.</u>	<u>Common</u> <u>See (1)</u> <u>Below.</u>	<u>N/A</u> <u>See (1)</u> <u>Below.</u>	<u>N/A</u> <u>See (1)</u> <u>Below.</u>	<u>Jack Farley,</u> <u>Lorie Farley</u> <u>See (1)</u> <u>Below.</u>	<u>N/A</u> <u>See (1)</u> <u>Below.</u>	<u>Restricted</u> <u>See (1)</u> <u>Below.</u>	<u>Exempt</u> <u>See (1)</u> <u>Below.</u>
<u>09/10/2021</u>	<u>Cancellation</u> <u>See (2)</u> <u>Below.</u>	<u>549,385.987</u> <u>See (2)</u> <u>Below.</u>	<u>Common</u> <u>See (2)</u> <u>Below.</u>	<u>N/A</u> <u>See (2)</u> <u>Below.</u>	<u>N/A</u> <u>See (2)</u> <u>Below.</u>	<u>Multiple</u> <u>shareholders</u> <u>See (2)</u> <u>Below.</u>	<u>N/A</u> <u>See (2)</u> <u>Below.</u>	<u>Restricted</u> <u>See (2)</u> <u>Below.</u>	<u>Exempt</u> <u>See (2)</u> <u>Below.</u>
<u>12/20/2001</u>	<u>New Issuance</u>	<u>15,000.000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.001</u>	<u>No</u>	<u>Omnis Public</u> <u>Capital</u> <u>Management</u> <u>LLC (Miguel</u> <u>Sanchez)</u>	<u>Purchase of</u> <u>Subsidiary</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>03/31/2023</u>	<u>New Issuance</u>	<u>12,500</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.40</u>	<u>No</u>	<u>Wayne Beita</u>	<u>Cash</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>03/31/2023</u>	<u>New Issuance</u>	<u>50,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.40</u>	<u>No</u>	<u>Benjamin</u> <u>Holcomb</u>	<u>Cash</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>03/31/2023</u>	<u>New Issuance</u>	<u>25,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.40</u>	<u>No</u>	<u>Pink</u> <u>Hospitality</u> <u>Group LLC</u> <u>(Sam Pink)</u>	<u>Cash</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>03/31/2023</u>	<u>New Issuance</u>	<u>25,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.40</u>	<u>No</u>	<u>Enrique Perez</u>	<u>Cash</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>03/31/2023</u>	<u>New Issuance</u>	<u>250,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.40</u>	<u>No</u>	<u>JJ Enterprises</u> <u>LLC (José</u> <u>Piñeda)</u>	<u>Cash</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>Cancellation</u>	<u>15,000.000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.001</u> <u>Par</u> <u>Value</u>	<u>No</u>	<u>Omnis Public</u> <u>Capital</u> <u>Management</u> <u>LLC (Miguel</u> <u>Sanchez)</u>	<u>Split to</u> <u>individual</u> <u>owners</u>	<u>Restricted</u>	<u>Exempt</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>5,000,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.001</u> <u>Par</u> <u>Value</u>	<u>No</u>	<u>Miguel</u> <u>Sanchez</u>	<u>Split to</u> <u>individual</u> <u>owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>3,000,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.001</u> <u>Par</u> <u>Value</u>	<u>No</u>	<u>Patrick</u> <u>Ashiofu</u>	<u>Split to</u> <u>individual</u> <u>owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>3,000,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.001</u> <u>Par</u> <u>Value</u>	<u>No</u>	<u>Luis Beita</u>	<u>Split to</u> <u>individual</u> <u>owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>1,500,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.001</u> <u>Par</u> <u>Value</u>	<u>No</u>	<u>Ankit Amin</u>	<u>Split to</u> <u>individual</u> <u>owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>1,500,000</u>	<u>Series B</u> <u>Preferred</u>	<u>\$0.001</u> <u>Par</u> <u>Value</u>	<u>No</u>	<u>Carey W.</u> <u>Cooley</u>	<u>Split to</u> <u>individual</u> <u>owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>04/25/2023</u>	<u>New Issuance</u>	<u>20,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Jean Paul Garzon</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>20,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Manuel Gonzalez</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>4,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Alfonso Gonzalez</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>5,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Sebastian Agudelo</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>6,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Fabio Avila</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>2,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Veronica Montgomery</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>2,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Ivan Sanchez</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>2,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Orlando Gonzalez</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>2,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Nick Minjares</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>2,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Maria Rebollar</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>12,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Jason Mendez</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>5,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Alejandro Garza</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>10,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Elizabeth Sacks</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>10,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>José Piñeda</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>3,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Randall Williams</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>

<u>04/25/2023</u>	<u>New Issuance</u>	<u>5,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Paula Rios</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>50,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Garvin Jobs</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>10,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Ximena Cuevas</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>5,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Octavio Garcia</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>5,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>David Olivos</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
<u>04/25/2023</u>	<u>New Issuance</u>	<u>820,000</u>	<u>Series B Preferred</u>	<u>\$0.001 Par Value</u>	<u>No</u>	<u>Omnis Public Capital Management LLC (Miguel Sanchez)</u>	<u>Split to individual owners</u>	<u>Restricted</u>	<u>4(a)(2)</u>
_____	_____	_____	_____	_____	_____	_____	_____	_____	_____
Shares Outstanding on Date of This Report:									
<u>Ending Balance</u>									
Date <u>05/31/2023</u>	Common:	<u>966,442,572</u>							
	Preferred:	<u>16,612,501</u>							

- (1) In July 2021, the Company entered an agreement with a former officer to purchase 565,000,000 shares owned by the officer and the officer's deceased spouse that were subject to cancellation by the Court. The purchase price was \$30,000.00. The former officer returned certificates representing 395,000,000 shares, which were officially cancelled by the transfer agent on July 28, 2021.
- (2) On September 9, 2021, the Custodian filed a Petition and Motion for Amended Order with the District Court of Clark County, Nevada, to include language satisfactory to the Company's transfer agent for the cancellation of shares without a physical certificate. On September 10, 2021, the Court approved the amended order. Pursuant to the order, 549,385,987 shares were cancelled by the transfer agent on September 22, 2021, with an effective date of September 10, 2021.

## B. Promissory and Convertible Notes

Indicate by check mark whether there are any outstanding promissory, convertible notes, convertible debentures, or any other debt instruments that may be converted into a class of the issuer's equity securities:

No: ☒ Yes: ☐ (If yes, you must complete the table below)



Date of Note Issuance	Outstanding Balance (\$)	Principal Amount at Issuance (\$)	Interest Accrued (\$)	Maturity Date	Conversion Terms (e.g. pricing mechanism for determining conversion of instrument to shares)	Name of Noteholder. <small>*You must disclose the control person(s) for any entities listed.</small>	Reason for Issuance (e.g. Loan, Services, etc.)
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____
_____	_____	_____	_____	_____	_____	_____	_____

Use the space below to provide any additional details, including footnotes to the table above:

\_\_\_\_\_

#### 4) Issuer's Business, Products and Services

The purpose of this section is to provide a clear description of the issuer's current operations.  
(Please ensure that these descriptions are updated on the Company's Profile on [www.otcmarkets.com](http://www.otcmarkets.com)).

- A. Summarize the issuer's business operations (If the issuer does not have current operations, state "no operations")

AVVAA World Health Care Products, Inc. operates through its wholly owned subsidiary, GoldQuest Capital, Inc. GOLDQUEST CAPITAL, INC. is a Houston, Texas-based real estate lending company that specializes in syndicating first lien, asset-backed real estate mortgages in the residential, commercial, and industrial sectors.

- B. List any subsidiaries, parent company, or affiliated companies.

GoldQuest Capital, Inc.

- C. Describe the issuers' principal products or services.

Syndication and financing of real estate mortgages.

#### 5) Issuer's Facilities

The goal of this section is to provide a potential investor with a clear understanding of all assets, properties or facilities owned, used or leased by the issuer and the extent in which the facilities are utilized.

In responding to this item, please clearly describe the assets, properties or facilities of the issuer, give the location of the principal plants and other property of the issuer and describe the condition of the properties. If the issuer does not have complete ownership or control of the property (for example, if others also own the property or if there is a mortgage on the property), describe the limitations on the ownership.

If the issuer leases any assets, properties or facilities, clearly describe them as above and the terms of their leases.

The company operates in leased professional office space located at: 1001 West Loop South, Ste 803 Houston, TX 77027.

#### 6) Officers, Directors, and Control Persons

Using the table below, please provide information, as of the period end date of this report, regarding any officers, or directors of the company, individuals or entities controlling more than 5% of any class of the issuer's securities, or any person that performs a similar function, regardless of the number of shares they own. **If any insiders listed are corporate shareholders or entities, provide the name and address of the person(s) beneficially owning or controlling such corporate shareholders, or the name and contact information (City, State) of an individual representing the corporation or entity in the note section.**

Include Company Insiders who own any outstanding units or shares of any class of any equity security of the issuer.

The goal of this section is to provide an investor with a clear understanding of the identity of all the persons or entities that are involved in managing, controlling or advising the operations, business development and disclosure of the issuer, as well as the identity of any significant or beneficial shareholders.

Names of All Officers, Directors and Control Persons	Affiliation with Company (e.g. Officer Title /Director/Owner of more than 5%)	Residential Address (City / State Only)	Number of shares owned	Share type/class	Ownership Percentage of Class Outstanding	Names of control person(s) if a corporate entity
Miguel Sanchez	President, Treasurer, CEO, Director, Owner of more than 5%	Houston, TX	5,000,000	Series B Preferred	32.55%	
Patrick Ashiofu	Director, Owner of more than 5%	Houston, TX	3,000,000	Series B Preferred	19.53%	
Luis Beita	Director, Owner of more than 5%	Houston, TX	3,000,000	Series B Preferred	19.53%	
Omnis Public Capital Management LLC	Owner of more than 5%	Houston, TX	1	Special 2021 Series A Preferred	100%	See Below (1)
			820,000	Series B Preferred	5.34%	
Carey W Cooley	Secretary, Director, Owner of more than 5%	Sugar Land, TX	1,500,000	Series B Preferred	9.76%	
Ankit Amin	Director, Owner of more than 5%	Houston, TX	1,500,000	Series B Preferred	9.76%	

- 1) Omnis Public Capital Management LLC with an address at 1001 West Loop South, Suite 803, Houston, TX 77027, is owned by Miguel Sanchez, Patrick Ashiofu, and Luis Beita. Omnis Public Capital Management LLC owns one (1) share of Special 2021 Series A Preferred Stock, which represents 100% of the issued and outstanding shares. The Special 2021 Series A Preferred Stock collectively has 60% voting rights, and each share can be converted into 2,000,000 shares of common stock. Omnis Public Capital Management LLC owns 820,000 shares of Class B Preferred Share, which represents 5.34% of the issued and outstanding shares. Each share of Series B Preferred Stock can be converted into 100 shares of common stock.

## 7) Legal/Disciplinary History

A. Identify whether any of the persons or entities listed above have, in the past 10 years, been the subject of:

1. A conviction in a criminal proceeding or named as a defendant in a pending criminal proceeding (excluding traffic violations and other minor offenses);

No.

2. The entry of an order, judgment, or decree, not subsequently reversed, suspended or vacated, by a court of competent jurisdiction that permanently or temporarily enjoined, barred, suspended or otherwise limited such person's involvement in any type of business, securities, commodities, or banking activities;

No.

3. A finding or judgment by a court of competent jurisdiction (in a civil action), the Securities and Exchange Commission, the Commodity Futures Trading Commission, or a state securities regulator of a violation of federal or state securities or commodities law, which finding or judgment has not been reversed, suspended, or vacated; or

No.

4. The entry of an order by a self-regulatory organization that permanently or temporarily barred, suspended, or otherwise limited such person's involvement in any type of business or securities activities.

No.

- B. Describe briefly any material pending legal proceedings, other than ordinary routine litigation incidental to the business, to which the issuer or any of its subsidiaries is a party or of which any of their property is the subject. Include the name of the court or agency in which the proceedings are pending, the date instituted, the principal parties thereto, a description of the factual basis alleged to underlie the proceeding and the relief sought. Include similar information as to any such proceedings known to be contemplated by governmental authorities.

None.

## 8) Third Party Service Providers

Provide the name, address, telephone number and email address of each of the following outside providers. You may add additional space as needed.

Securities Counsel (must include Counsel preparing Attorney Letters).

Name: Jonathan D. Leinwand  
Address 1: 18305 Biscayne Blvd, Suite 200  
Address 2: Aventura, FL 33160  
Phone: 954-903-7856  
Email: jonathan@jdpa.com

Accountant or Auditor

Name: Tyrus C Young  
Firm: Factsco, LLC  
Address 1: 11117 Saintsbury Place  
Address 2: Charlotte, NC 28270  
Phone: 727-470-8684  
Email: factsco@gmail.com

Investor Relations

Name: \_\_\_\_\_  
Firm: \_\_\_\_\_  
Address 1: \_\_\_\_\_  
Address 2: \_\_\_\_\_  
Phone: \_\_\_\_\_

Email: \_\_\_\_\_

*All other means of Investor Communication:*

Twitter: @GoldQuestCap

Discord: \_\_\_\_\_

LinkedIn: \_\_\_\_\_

Facebook: \_\_\_\_\_

[Other ] \_\_\_\_\_

#### Other Service Providers

Provide the name of any other service provider(s) that **that assisted, advised, prepared, or provided information with respect to this disclosure statement**. This includes counsel, broker-dealer(s), advisor(s), consultant(s) or any entity/individual that provided assistance or services to the issuer during the reporting period.

Name: \_\_\_\_\_

Firm: \_\_\_\_\_

Nature of Services: \_\_\_\_\_

Address 1: \_\_\_\_\_

Address 2: \_\_\_\_\_

Phone: \_\_\_\_\_

Email: \_\_\_\_\_

### **9) Financial Statements**

A. The following financial statements were prepared in accordance with:

☐ IFRS

☒ U.S. GAAP

B. The following financial statements were prepared by (name of individual)<sup>2</sup>:

Name: **Tyrus C. Young**

Title: **Consultant**

Relationship to Issuer: **Consultant**

Describe the qualifications of the person or persons who prepared the financial statements:

CPA/Consultant for over 40 years, and over 10 years in preparing the financial statements, disclosure statements and notes to the financial statements submitted to OTC.

Provide the following financial statements for the most recent fiscal year or quarter. For the initial disclosure statement (qualifying for Pink Current Information for the first time) please provide reports for the two previous fiscal years and any subsequent interim periods.

- a. Audit letter, if audited;
- b. Balance Sheet;
- c. Statement of Income;
- d. Statement of Cash Flows;
- e. Statement of Retained Earnings (Statement of Changes in Stockholders' Equity)
- f. Financial Notes

---

<sup>2</sup> The financial statements requested pursuant to this item must be prepared in accordance with US GAAP or IFRS and by persons with sufficient financial skills.

Important Notes:

- Financial statements must be “machine readable”. Do not publish images/scans of financial statements.
- All financial statements for a fiscal period must be published together with the disclosure statement in one Annual or Quarterly Report.

## 10) Issuer Certification

*Principal Executive Officer:*

The issuer shall include certifications by the chief executive officer and chief financial officer of the issuer (or any other persons with different titles but having the same responsibilities) in each Quarterly Report or Annual Report.

The certifications shall follow the format below:

I, Miguel Sanchez certify that:

1. I have reviewed this Disclosure Statement for AVVAA World Health Care Products, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

09/20/2023

/s/ Miguel Sanchez, President/CEO

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

*Principal Financial Officer:*

I, Miguel Sanchez certify that:

1. I have reviewed this Disclosure Statement for AVVAA World Health Care Products, Inc.;
2. Based on my knowledge, this disclosure statement does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this disclosure statement; and
3. Based on my knowledge, the financial statements, and other financial information included or incorporated by reference in this disclosure statement, fairly present in all material respects the financial condition, results of operations and cash flows of the issuer as of, and for, the periods presented in this disclosure statement.

09/20/2023

/s/ Miguel Sanchez, Treasurer

(Digital Signatures should appear as “/s/ [OFFICER NAME]”)

**AVVAA WORLD HEALTH CARE PRODUCTS, INC.**

**INDEX TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS**

	<b><u>Page</u></b>
Financial Statements	
Unaudited Consolidated Balance Sheet as of May 31, 2023 and May 31, 2022	F-2
Unaudited Consolidated Statement of Operations for the years ended May 31, 2023 and 2022	F-3
Unaudited Consolidated Statement of Cash Flows for the years ended May 31, 2023 and 2022	F-4
Unaudited Consolidated Statement of Stockholders' Deficit for the periods ended May 31, 2021 through May 31, 2023	F-5
Unaudited Notes to Financial Statements	F-6

**AVVAA WORLD HEALTH CARE PRODUCTS, INC.**  
**CONDENSED CONSOLIDATED BALANCE SHEET**  
**(UNAUDITED)**

	<b>May 31, 2023</b>	<b>May 31, 2022</b>
<b>ASSETS</b>		
Current Assets:		
Cash	\$ 49,124	\$ 126,603
Total current assets	49,124	126,603
Other assets		
Organizational Costs, Net	\$ 136,687	\$ 146,450
<b>TOTAL ASSETS</b>	<b>\$ 185,811</b>	<b>\$ 273,053</b>
<b>LIABILITIES &amp; STOCKHOLDERS' DEFICIT</b>		
Current Liabilities:		
Accounts payable	\$ 61,965	\$ 87,200
Advances by Shareholder	3,377	3,377
Total Current Liabilities	\$ 65,342	\$ 90,577
Notes payable to shareholder	-	-
<b>Total Liabilities</b>	<b>\$ 65,342</b>	<b>\$ 90,577</b>
<b>Stockholders' Equity (Deficit)</b>		
Preferred Stock, \$0.001 par value, 420,000,000 shares authorized		
Special 2021 Series A preferred, \$0.001 par value, 1 share authorized and 1 share issued and outstanding at May 31, 2023 and 2022.		
Class A Convertible Super preferred stock, \$0.001 par value, 400,000,000 shares authorized, and 1,250,000 shares issued and outstanding at May 31, 2023 and May 31, 2022.		
Series B preferred stock, \$0.001 par value, 20,000,000 shares authorized, and 15,362,500 shares issued and outstanding at May 31 2023 and 15,000,000 at May 31, 2022.	16,613	16,250
Common stock, \$0.001 par value, 4,000,000,000 shares authorized		
966,442,572 shares issued and outstanding at May 31, 2023	966,443	966,443
946,442,572 shares issued and outstanding at May 31, 2022		
Shares to be Issued	-	150,000
Additional Paid-In Capital	30,129,370	29,979,732
Accumulated deficit	(30,991,956)	(30,929,949)
<b>Total Stockholders' Deficit</b>	<b>120,469</b>	<b>182,476</b>
<b>TOTAL LIABILITES &amp; STOCKHOLDERS' EQUITY</b>	<b>\$ 185,811</b>	<b>\$ 273,053</b>

The accompanying notes are an integral part of these financial statements.

**AVVAA WORLD HEALTH CARE PRODUCTS, INC.**  
**CONSOLIDATED STATEMENT OF OPERATIONS**  
**(UNAUDITED)**

	<b>For the years ended</b>	
	<b>May 31, 2023</b>	<b>May 31, 2022</b>
Revenues		
Cost of Revenues	\$ 60,000	\$ -
General & Administrative	58,000	-
Gross Profit	2,000	-
Operating expenses		
General & Administrative	54,244	28,974
Total Operating Expenses	54,244	28,974
Net Operating Income (Loss)	\$ (52,244)	\$ (28,974)
Other Income (Expense)		
Amortization Expense	(9,763)	-
Total Other Income (Expense)	(9,763)	-
<b>NET INCOME (LOSS)</b>	<b>\$ (62,007)</b>	<b>\$ (28,974)</b>
BASIC AND DILUTED LOSS PER SHARE:		
Net loss per common share - basic and diluted	\$ (0.00)	\$ (0.00)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:		
Basic	966,442,572	966,442,572

The accompanying notes are an integral part of these financial statements.



**AVVAA WORLD HEALTH CARE PRODUCTS, INC.**  
**CONSOLIDATED STATEMENT OF CASH FLOWS**  
**(UNAUDITED)**

	<b>For the years ended</b>	
	<b>May 31, 2023</b>	<b>May 31, 2022</b>
<b>Cash flows from operations</b>		
Net income(loss)	\$ (62,007)	\$ (28,974)
Amortization expense	9,763	-
Increase in Organizational Costs		\$ (85,000)
Increase in Accounts Payable	(25,235)	87,200
Increase in Shareholder Advance	-	3,377
<b>Net cash provided/used by operating activities</b>	<b>(77,479)</b>	<b>(23,397)</b>
<b>Cash flows from investing activities</b>	<b>-</b>	<b>-</b>
<b>Net cash provided/used by investing activities</b>	<b>-</b>	<b>-</b>
<b>Cash flows from financing activities</b>		
Common stock purchased (issued 3/23)	-	150,000
<b>Net cash provided/used by financing activities</b>	<b>-</b>	<b>150,000</b>
<b>Net increase (decrease) in cash</b>	<b>(77,479)</b>	<b>126,603</b>
<b>Cash and Cash Equivalents - Beginning of Period</b>	<b>126,603</b>	<b>-</b>
<b>Cash and Cash Equivalents - End of Period</b>	<b>\$ 49,124</b>	<b>\$ 126,603</b>

The accompanying notes are an integral part of these financial statements.

AVVAA WORLD HEALTH CARE PRODUCTS, INC.

CONSOLIDATED STATEMENT OF CHANGES IN STOCKHOLDERS' DEFICIT  
(UNAUDITED)

	Common Stock		Class A Preferred Stock		Special 2021 Series A Preferred Stock		Series B Preferred Stock		Shares to be	Additional	Accumulated	
	# of Shares	Amount					# of Shares	Amount	Issued	Paid-in Capital	Deficit	TOTAL
Balance - May 31, 2021	1,910,828,559	\$ 1,910,829	1,250,000	\$ 1,250	1	\$ -	-	\$ -	-	\$ 28,988,896	\$ (30,900,975)	\$ -
Share cancellation	(944,385,987)	\$ (944,386)								944,386		-
Shares issued for Gold Quest Capital							15,000,000	15,000		46,450		61,450
Stock issued for cash									150,000			150,000
Net Income(Loss)	-	-	-	-	-	-	-	-	-	-	(28,974)	(28,974)
Balance - May 31, 2022	966,442,572	\$ 966,443	1,250,000	\$ 1,250	1	\$ -	15,000,000	\$ 15,000	150,000	\$ 29,979,732	\$ (30,929,949)	\$ 182,476
Preferred stock issued							362,500	363	(150,000)	149,638		0
Net Income(Loss)	-	-	-	-	-	-	-	-	-	-	(62,007)	(62,007)
Balance - May 31, 2023	966,442,572	\$ 966,443	1,250,000	\$ 1,250	1	\$ -	15,362,500	\$ 15,363	-	\$ 30,129,370	\$ (30,991,956)	\$ 120,469

The accompanying notes are an integral part of these financial statements.

AVVAA WORLD HEALTH CARE PRODUCTS, INC.  
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
MAY 31, 2023  
(Unaudited)

**NOTE 1 – ORGANIZATION AND NATURE OF OPERATIONS**

AVVAA World Health Care Products, Inc. (the "Company", "we", "us" or "our"), a Nevada corporation, has a fiscal year end of May 31 and is listed on the OTC Pink Markets under the trading symbol AVVH. The Company had ceased operations but not taken steps to dissolve, liquidate and distribute its assets. The Company was incorporated on June 3, 1998 in the State of Nevada as Sierra Gigante Resources, Inc.

In June 2002, the Company completed the acquisition of 100% of the common shares of Mind Your Own Skin Products Inc. ("MYOSP"), a company incorporated under the Company Act of the Province of British Columbia, Canada. This share issuance resulted in a reverse takeover of the Company by the shareholders of MYOSP. Certain directors and officers of MYOSP became directors and officers of the Company.

In July 2002, the Company filed an Amendment to the Articles of Incorporation to change its name to AVVAA World Health Care Products, Inc. The Company's primary business was the distribution and sale of over-the-counter all-natural therapeutic skin care products designed to treat the symptoms of skin diseases such as eczema, psoriasis, and acne.

Required repolliing requirements with the Nevada Secretary of State, the failure to hold an annual meeting of stockholders and pay its annual franchise tax from 2014 to 2020 resulted in its Nevada charter being revoked. The Company also did not provide adequate current public information as defined in Rule 144, promulgated under the Securities Act of 1933, and was thus subject to revocation by the Securities and Exchange Commission pursuant to Section 12(k) of the Exchange Act.

On November 5, 2020, SSM Monopoly Corporation, a shareholder of the Company, served a demand to the Company, at last address of record, to comply with the Nevada Secretary of State statutes N.R.S. 78.710 and N.R.S. 78.150. On December 8, 2020, a petition was filed against the Company in the District Court of Clark County, Nevada, entitled "In the Matter of AVVAA World Health Care Products, Inc., a Nevada corporation" under case number A-20-825998- C by SSM Monopoly Corporation, along with an Application for Appointment of Custodian, after several attempts to locate prior management and reinstate the Company's Nevada charter, which had been revoked. The District Court, Clark County, Nevada and was appointed as the custodian of the Company in January 2021.

On January 25, 2021, the District Court of Clark County, Nevada entered an Order Granting Application for Appointment of SSM Monopoly Corporation (the "Order"), as Custodian of the Company. Pursuant to the Order, the SSM Monopoly Corporation (the "Custodian") has the authority to take any actions on behalf of the Company, that are reasonable, prudent or for the benefit of pursuant to, including, but not limited to, issuing shares of stock and issuing new classes of stock, as well as entering in contracts on behalf of the Company.

Also, on January 25, 2021, the Custodian granted to itself, one share of preferred stock, Special 2021 Series A Preferred Stock ("2021 Series A Preferred") at par value of \$0.001. The 2021 Series A Preferred has 60% voting rights over all classes of stock and convertible into 2,000,000,000 shares of the Company's common stock.

Also on January 25, 2021, the Custodian appointed Kareem Mansour as the Company's sole officer and director.

On January 27, 2021, in a private transaction, the Custodian entered into a Securities Purchase Agreement (the "SPA") with Krisa Management LLC, a Texas limited liability company, to sell the 2021 Series A Preferred. Upon closing of the SPA on January 27, 2021, Krisa Management LLC acquired 60% control of the Company. Also on January 27, 2021, the Custodian appointed Carey W. Cooley as the Company's sole officer and director. On January 27, 2021, Kareem Mansour resigned as an officer and director of the Company.

On February 5, 2021, the Company filed a Certificate of Revival with the Secretary State of the State of Nevada, which reinstated the Company's charter and appointed a new Resident Agent in Nevada.

AVVAA WORLD HEALTH CARE PRODUCTS, INC.  
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
MAY 31, 2023  
(Unaudited)

On April 12, 2021, at a Specially Called Meeting of all of the Officers and Directors of the Company, a resolution was ratified and adopted canceling 1,012,385,987 shares of common stock issued by previous management after a Cease Trade Order issued by the British Columbia Securities Commission had gone into effect in Canada on October 1, 2009. The Court Appointed Custodian also ratified and adopted a resolution canceling certain shares as in the best interest of the Corporation.

On April 26, 2021, in a private transaction, Krisa Management LLC entered into a Securities Purchase Agreement (the "SPA") with Omnis Public Capital Management LLC, a Texas limited liability company, to sell the 2021 Series A Preferred. Upon closing of the SPA on May 3, 2021, Omnis Public Capital Management LLC acquired 60% control of the Company.

On June 14, 2021, the Custodian filed a Motion to Discharge Custodian (the "Motion") in the District Court of Clark County, Nevada. On July 1, 2021, the Motion was amended to remove 68,000,000 shares from the resolution canceling shares, leaving 944,385,987 shares of common stock to be canceled.

On July 8, 2021, prior to the Court ruling on the Motion to Discharge, the Custodian entered into an Agreement with a shareholder (the "Shareholder") to purchase back some of the shares covered by the resolution to cancel shares. Pursuant to the Agreement, 565,000,000 shares of common stock beneficially owned by the Shareholder were purchased back for \$30,000. On July 28, 2021, certificates for 395,000,000 of these shares were canceled by the Company upon return. The certificates for the other 170,000,000 of these shares were lost and were awaiting additional documentation from the Shareholder.

On July 15, 2021, the District Court of Clark County, Nevada entered a Final Order Granting the Motion to Discharge Custodianship to accept all actions taken by the Custodian (including the cancellation of 944,385,987 shares of common stock) and to dismiss the Custodian's authority and control over the Company under the Custodianship. On the same day, Omnis Public Capital Management LLC gained authority and control of the Company through voting rights and the court order.

On September 9, 2021, the Custodian filed a Petition and Motion for Amended Order with the District Court of Clark County, Nevada, to include language satisfactory to the Company's transfer agent for the cancellation of shares without a physical certificate. On September 10, 2021, the Court approved the amended order. Pursuant to the amended order, 549,385,987 shares were cancelled by the transfer agent on September 22, 2021, with an effective date of September 10, 2021.

On December 20, 2021, the Company acquired GoldQuest Capital, Inc as a wholly owned subsidiary.

## **NOTE 2 - BASIS OF PRESENTATION AND GOING CONCERN**

### **Basis of Presentation**

The Company has not earned any revenues from limited principal operations. Accordingly, the Company's activities have been accounted for as those of a "Development Stage Enterprise" as set forth in Financial Accounting Standards Board Statement No. 7 ("SFAS 7"). Among the disclosures required by SFAS 7 are that the Company's financial statements be identified as those of a development stage company, and that the statements of operations, stockholders' equity (deficit) and cash flows disclose activity since the date of the Company's inception.

### **Basis of Accounting**

The accompanying consolidated financial statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States. All intercompany transactions have been eliminated.

AVVAA WORLD HEALTH CARE PRODUCTS, INC.  
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
MAY 31, 2023  
(Unaudited)

**Going Concern**

The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of assets and the liquidation of liabilities in the normal course of business. The Company currently has no operations with an accumulated deficit of \$30,946,476 as of May 31, 2023. The Company intends to commence operations as set out below and raise the necessary funds to carry out the aforementioned strategies. The Company cannot be certain that it will be successful in these strategies even with the required funding.

These factors, among others, raise substantial doubt about the Company's ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

**NOTE 3 - SIGNIFICANT ACCOUNTING POLICIES**

**Use of Estimates**

The preparation of financial statements in conformity with U.S. generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

**Cash and Cash Equivalents**

For purposes of the statement of cash flows, cash equivalents include demand deposits, money market funds, and all highly liquid debt instruments with original maturities of three months or less.

**Financial Instruments**

The FASB issued ASC 820-10, Fair Value Measurements and Disclosures, for financial assets and liabilities. ASC 820-10 provides a framework for measuring fair value and requires expanded disclosures regarding fair value measurements. ASC 820-10 defines fair value as the price that would be received for an asset or the exit price that would be paid to transfer a liability in the principal or most advantageous market in an orderly transaction between market participants on the measurement date. ASC 820-10 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs, where available. The following summarizes the three levels of inputs required by the standard that the Company uses to measure fair value:

Level I: Quoted prices in active markets for identical assets or liabilities

Level 2: Observable inputs other than Level I prices, such as quoted prices for similar assets or liabilities; quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the related assets or liabilities.

Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities.

**Concentrations and Credit Risks**

The Company's financial instruments that are exposed to concentrations and credit risk primarily consist of its cash, sales and accounts receivable. The Company places its cash and cash equivalents with financial institutions of high creditworthiness. At times, its cash and cash equivalents with a particular financial institution may exceed any applicable government insurance limits. The Company's management plans to assess the financial strength and credit

AVVAA WORLD HEALTH CARE PRODUCTS, INC.  
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
MAY 31, 2023  
(Unaudited)

wholeness of any parties to which it extends funds, and as such, it believes that any associated credit risk exposures are limited.

Foreign Currency Translation

The accounts of the Company are accounted for in accordance with the Statement of Financial Accounting Standards No. 52 ("SFAS 52"), "Foreign Currency Translation". The financial statements of the Company are translated into US dollars as follows: assets and liabilities at year-end exchange rates; income, expenses and cash flows at average exchange rates; and shareholders' equity at historical exchange rate.

Monetary assets and liabilities, and the related revenue, expense, gain and loss accounts, of the Company are re-measured at year-end exchange rates. Non-monetary assets and liabilities, and the related revenue, expense, gain and loss accounts are re-measured at historical rates. Adjustments which result from the re-measurement of the assets and liabilities of the Company are included in net income.

Share-Based Compensation

ASC 718, Compensation - Stock Compensation, prescribes accounting and reporting standards for all share-based payment transactions in which employee services are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options, and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized in the period of grant.

The Company accounts for stock-based compensation issued to non-employees and consultants in accordance with the provisions of ASC 505-50, Equity - Based Payments to Non-Employees. Measurement of share-based payment transactions with non-employees is based on the fair value of whichever is more reliably measurable: (a) the goods or services received; or (b) the equity instruments issued. The fair value of the share-based payment transaction is determined at the earlier of performance commitment date or performance completion date.

As of May 31, 2023 and 2022, respectively, there was \$Nil of unrecognized expense related to non-vested stock-based compensation arrangements granted. There have been no options granted during the three months ended May 31, 2023 and 2022, respectively.

Income Taxes

The Company accounts for income taxes under ASC 740, Income Taxes. Under the asset and liability method of ASC 740, deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statements carrying amounts of existing assets and liabilities and their respective tax bases. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period the enactment occurs. A valuation allowance is provided for certain deferred tax assets if it is more likely than not that the Company will not realize tax assets through future operations. Deferred tax assets or liabilities were offset by a 100% valuation allowance, therefore there has been no recognized benefit as of August 31, 2022 and 2021, respectively. Further it is unlikely with the change of control that the Company will have the ability to realize any future tax benefits that may exist.

Commitments and Contingencies

The Company follows ASC 450-20, Loss Contingencies, to report accounting for contingencies. Liabilities for loss contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

AVVAA WORLD HEALTH CARE PRODUCTS, INC.  
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
MAY 31, 2023  
(Unaudited)

Earnings Per Share

Net income (loss) per share is calculated in accordance with ASC 260, Earnings Per Share. The weighted-average number of common shares outstanding during each period is used to compute basic earnings or loss per share. Diluted earnings or loss per share is computed using the weighted average number of shares and diluted potential common shares outstanding. Dilutive potential common shares are additional common shares assumed to be exercised.

Basic net income (loss) per common share is based on the weighted average number of shares of common stock outstanding at May 31, 2023 and 2022. Due to net operating loss, there is no presentation of dilutive earnings per share, as it would be anti-dilutive.

Forgiveness of Indebtedness

The Company follows the guidance of AS 470.10 related to debt forgiveness and extinguishment. Debts of the Company are considered extinguished when the statute of limitations in the applicable jurisdiction expires or when terminated by judicial authority such as the granting of a declaratory judgment. Debts to related parties or shareholders are treated as capital transactions when forgiven or extinguished and credited to additional paid in capital. Debts to non-related parties are treated as other income when forgiven or extinguished.

Recent Accounting Pronouncements

We have reviewed all the recently issued, but not yet effective, accounting pronouncements and we do not believe any of these pronouncements will have a material impact on the Company.

In August 2017, the FASB issued ASU No. 2017-12, Derivatives and Hedging (Topic 815), which changes both the designation and measurement guidance for qualifying hedging relationships and the presentation of hedge results, in order to better align an entity's risk management activities and financial reporting for hedging relationships. The amendments expand and refine hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. FASB ASU No. 2017-12 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, with early adoption permitted. We are still evaluating the impact that this guidance will have on our financial position or results of operations, and we have not yet determined whether we will early adopt FASB ASU No. 2017-12.

In March 2016, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2016-09, Compensation - Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting. This guidance changes how companies account for certain aspects of share-based payments to employees. Among other things, under the new guidance, companies will no longer record excess tax benefits and certain tax deficiencies in additional paid-in-capital ("APIC"), but will instead record such items as income tax expense or benefit in the income statement, and APIC pools will be eliminated. Companies will apply this guidance prospectively. Another component of the new guidance allows companies to make an accounting policy election for the impact of forfeitures on the recognition of expense for share-based payment awards, whereby forfeitures can be estimated, as required today, or recognized when they occur. If elected, the change to recognize forfeitures when they occur needs to be adopted using a modified retrospective approach. All of the guidance will be effective for the Company in the fiscal year beginning January 1, 2018. Early adoption is permitted. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

In February 2016, the FASB issued ASU No. 2016-02, leases (Topic 842), which establishes new accounting and disclosure requirements for leases. FASB ASU No. 2016-02 requires lessees to classify most leases as either finance or operating leases and to initially recognize a lease liability and right-of-use asset. Entities may elect to account for certain short-term leases (with a term of 12 months or less) using a method similar to the current operating lease model. The statements of operations will include, for finance leases, separate recognition of interest on the lease liability and amortization of the right-of-use asset and for operating leases, a single lease cost, calculated so that the

AVVAA WORLD HEALTH CARE PRODUCTS, INC.  
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
MAY 31, 2023  
(Unaudited)

cost of the lease is allocated over the lease term on a straight-line basis. While we are in the early stages of our implementation process for FASB ASU No. 2016-02, and have not yet determined its impact on our financial position or results of operations, these leases would potentially be required to be presented on the balance sheet in accordance with the requirements of FASB ASU No. 2016-02. FASB ASU No. 2016-02 is effective for annual reporting periods beginning after December 15, 2018, including interim periods within those annual reporting periods, with early adoption permitted. FASB ASU No. 2016-02 must be applied using a modified retrospective approach, which requires recognition and measurement of leases at the beginning of the earliest period presented, with certain practical expedients available.

In July 2015, the FASB issued ASU No. 2015-11, Inventory (Topic 330): Simplifying the Measurement of Inventory. The guidance requires an entity to measure inventory at the lower of cost or net realizable value, which is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation, rather than the lower of cost or market in the previous guidance. This amendment applies to inventory that is measured using first-in, first-out (FIFO). This amendment is effective for public entities for fiscal years beginning after December 15, 2016, including interim periods within those years. A reporting entity should apply the amendments prospectively with earlier application permitted as of the beginning of an interim or annual reporting period. The Company is currently evaluating the impact of this guidance, if any, on its financial statements and related disclosures.

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers ("ASU 2014-09"), which requires an entity to recognize the amount of revenue to which it expects to be entitled for the transfer of promised goods or services to customers. ASU 2014-09 will replace most existing revenue recognition guidance in U.S. generally accepted accounting principles when it becomes effective. In July 2015, the FASB deferred the effective date of the standard by an additional year; however, it provided companies the option to adopt one year earlier, commensurate with the original effective date. Accordingly, the standard will be effective for the Company in the fiscal year beginning January 1, 2018, with an option to adopt the standard for the fiscal year beginning January 1, 2017. The Company is currently evaluating this standard and has not yet selected a transition method or the effective date on which it plans to adopt the standard, nor has it determined the effect of the standard on its financial statements and related disclosures.

#### **NOTE 4 - INCOME TAXES**

Income taxes are provided based upon the liability method. Under this approach, deferred income taxes are recorded to reflect the tax consequences in future years of differences between the tax basis of assets and liabilities and their financial reporting amounts at each year-end. A valuation allowance is recorded against deferred tax assets if management does not believe the Company has met the "more likely than not" standard imposed by accounting standards to allow recognition of such an asset.

As of May 31, 2023, the Company expected no net deferred tax assets to be recognized, resulting from net operating loss carry forwards. Deferred tax assets were offset by a corresponding allowance of 100%.

The Company experienced a change in control in 2021, and therefore no more than an insignificant portion of this net operating allowance will ever be used against future taxable income.

#### **NOTE 4 - NOTES PAYABLE - RELATED PARTIES**

The Company has no Notes Payable to Related Parties, however, during the year ended May 31, 2022, one shareholder advanced \$3,377 for expenses.

#### **NOTE 5 - CONVERTIBLE NOTES PAYABLE**

There were no convertible notes payable during the period:



AVVAA WORLD HEALTH CARE PRODUCTS, INC.  
NOTES TO UNAUDITED CONSOLIDATED FINANCIAL STATEMENTS  
MAY 31, 2023  
(Unaudited)

**NOTE 6 - COMMITMENTS AND CONTINGENCIES**

*Risks and Uncertainties*

The Company's operations are subject to significant risks and uncertainties including financial, operational and regulatory risks, including the potential risk of business failure.

*Legal and other matters*

In the normal course of business, the Company may become a party to litigation matters involving claims against the Company. The Company's management is unaware of any pending or threatened assertions and there are no current matters that would have a material effect on the Company's financial position or results of operations.

**NOTE 7 - SUBSEQUENT EVENTS**

Management has evaluated subsequent events through the date of filing the consolidated financial statements with OTC Markets, the date the consolidated financial statements were available to be issued. Management is not aware of any significant events that occurred subsequent to the balance sheet date that would have a material effect on the consolidated financial statements thereby requiring adjustment or disclosure.

None.